Brilaroxazine 是一种有效的多模式多巴胺/5-HT 调节剂。 Brilaroxazine 是多巴胺 D2、D3 和 D4 受体、5-HT1A (Ki = 1.5 nM) 和 5-HT2A (Ki = 2.5 nM) 的部分激动剂，具有拮抗活性 5-HT2B 和 5-HT7 受体，Ki分别为 0.19 nM 和 2.7 nM。 Brilaroxazine 可用于研究神经精神和神经系统疾病的认知障碍。

Brilaroxazine is a potent multimodal dopamine/5-HT modulator. Brilaroxazine is a partial agonist of dopamine D2, D3, and D4 receptors, 5-HT1A (Ki =1.5 nM) and 5-HT2A (Ki = 2.5 nM), and has antagonist activity 5-HT2B, and 5-HT7 receptors with Kis of 0.19 nM and 2.7 nM, respectively. Brilaroxazine can be used for research about cognitive impairments in neuropsychiatric and neurological diseases.

Brilaroxazine (10 mg/kg) had efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH, with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes[3].

1239729-06-6

C22H25Cl2N3O3

450.36

RP5063;Brilaroxazine

DMSO:95 mg/mL (210.94 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years